European Institute of Oncology / Istituto Europeo di Oncologia (IEO)

Research / Science organisation


Location: Milano / Mailand, Italy (IT) IT

ISNI: 0000000417570843

ROR: https://ror.org/02vr0ne26

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study (2017) Higgins M, Curigliano G, Dieras V, Kuemmel S, Kunz G, Fasching P, Campone M, et al. Journal article PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1 (2017) Jiao X, Aravidis C, Marikkannu R, Rantala J, Picelli S, Adamovic T, Liu T, et al. Journal article Body mass index and breast cancer survival: a Mendelian randomization analysis (2017) Guo Q, Burgess S, Turman C, Bolla MK, Wang Q, Lush M, Abraham J, et al. Journal article Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer (2017) Guarneri V, Fasching P, Fernandez Abad M, Garcia-Saenz A, Schneeweiss A, Colleoni M, Petru E, et al. Conference contribution Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer (2017) Fasching P, Fernandez Abad M, Garcia-Saenz JA, Schneeweiss A, Guarneri V, Colleoni M, Petru E, et al. Conference contribution Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4 (2017) Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, et al. Journal article Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2017) Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, et al. Journal article rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk (2016) Liu J, Loncar I, Collee JM, Bolla MK, Dennis J, Michailidou K, Wang Q, et al. Journal article Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21 (2016) Hamdi Y, Soucy P, Adoue V, Michailidou K, Canisius S, Lemacon A, Droit A, et al. Journal article Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus (2016) Horne HN, Chung CC, Zhang H, Yu K, Prokunina-Olsson L, Michailidou K, Bolla MK, et al. Journal article
‹ 1 ... 6 7 8 9 10 ›